Showing results (611-620 of 662) with videos related to
Sort By:
Pageof 67
Immunity|August 17, 2017
Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor ProgressionYu Zhu, John M Herndon, Dorothy K Sojka, et al.Gut|December 3, 2017
Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinomaTimothy M Nywening, Brian A Belt, Darren R Cullinan, et al.Science Translational Medicine|July 5, 2019
Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapiesRoheena Z Panni, John M Herndon, Chong Zuo, et al.Cancer Immunology Research|May 25, 2023
Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic CancerC Alston James, John M Baer, Chong Zou, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2013
Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axisDominic E Sanford, Brian A Belt, Roheena Z Panni, et al.Journal of Cancer Therapy|October 4, 2013
A Study of Zoledronic Acid as Neo-Adjuvant, Perioperative Therapy in Patients with Resectable Pancreatic Ductal AdenocarcinomaDominic E Sanford, Matthew R Porembka, Roheena Z Panni, et al.Cancer Discovery|April 29, 2024
Senescence Defines a Distinct Subset of Myofibroblasts That Orchestrates Immunosuppression in Pancreatic CancerJad I Belle, Devashish Sen, John M Baer, et al.Cancer Immunology Research|February 7, 2020
B cell-Derived IL35 Drives STAT3-Dependent CD8+ T-cell Exclusion in Pancreatic CancerBhalchandra Mirlekar, Daniel Michaud, Samuel J Lee, et al.Cancer Immunology, Immunotherapy : CII|May 13, 2023
Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cancer immunobiologyUsman Y Panni, Michael Y Chen, Felicia Zhang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 24, 2025
Neoadjuvant BMS-813160, nivolumab, gemcitabine and nab-paclitaxel for patients with pancreatic cancerPatrick M Grierson, Crystal Wolf, Rama Suresh, et al.Pageof 67